[Skip to Content]
[Skip to Content Landing]
July 16, 1973

Medical News

JAMA. 1973;225(3):223-234. doi:10.1001/jama.1973.03220300003002

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


An antigen and an antibiotic may find use in tumor scanning  Work with two new tumor-scanning agents is showing encouraging results in animal studies and early clinical trials.Investigators from two institutions in the United States and Japan reported to the Society of Nuclear Medicine meeting in Miami Beach that the antibiotic, bleomycin, not only localizes in cancer tissue, but can be radioactively labeled.All of the groups found that the labeled bleomycin could be used to identify tumors. Some groups consider it to be the best tumor-scanning agent available, while others regard it either comparable to, or somewhat less effective than gallium 67, a relatively new scanning agent.The other tumor-scanning agent is radiolabeled carcinoembryonic antigen (CEA). A group of workers at the University of Chicago's Franklin McLean Memorial Research Institute found that CEA titers in bronchial washings from 32 patients were effective in diagnosing some, but not all